Co-Diagnostics, Inc. (CODX) · Nov 19, 2026 · Other events

Co-Diagnostics reverse split targets Nasdaq compliance as cash needs persist

1-for-25 reverse split — 1-for-25 split; approximately 521,779 shares afterward; $1.00 Nasdaq bid-price requirement

Co-Diagnostics’ reverse split keeps the stock Nasdaq-listed and preserves financing flexibility, but underscores the company’s funding pressure.

Co-Diagnostics is a cash-constrained molecular-diagnostics developer trying to commercialize its Co-Dx PCR platform while regulatory submissions for new tests remain under review. Its latest 10-Q reported only $714,803 of cash at September 30, 2026 and said continued operations depend on obtaining financing and eventually generating profitable operations.

The filing is a capital-markets defense, not a business advance. The board selected a 1-for-25 reverse split, effective November 24, after shareholders had already authorized a split of up to 1-for-750. The stated goals are maintaining Nasdaq’s $1.00 minimum bid requirement and keeping enough authorized shares available for future equity financing.

The practical benefit is preserving optionality while highlighting funding pressure. The split reduces outstanding shares from roughly 13.0 million to about 521,779, but it does not reduce the company’s authorized share count or create cash. Because the company’s latest filing already pointed to financing dependence, the ability to raise equity may matter more than the mechanical listing fix.

This was mostly expected, but the chosen ratio makes the pressure concrete. Shareholders approved the authority on November 13, so today’s filing confirms an anticipated action rather than introducing a new strategic direction. The 1-for-25 ratio is still a meaningful defensive measure, especially because Co-Diagnostics had already completed a 1-for-30 reverse split earlier in 2026 and had previously faced Nasdaq bid-price problems.

Bottom line: The split helps keep Co-Diagnostics listed and able to pursue financing, but it does not improve demand, regulatory progress, or cash generation. It modestly weakens the business read because another reverse split points to continued capital pressure rather than operating momentum.

What to watch next

Reverse split begins trading on a split-adjusted basis Nov. 24

Original filing on SEC EDGAR

More Co-Diagnostics, Inc. news

Co-Diagnostics reverse split targets Nasdaq compliance as cash needs persist | CODX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.